Short Stature
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Short stature is an emerging landscape with 20 programs across 12 companies. The most active players are BioMarin Pharmaceutical, EMD Serono, Esteve Pharmaceuticals, S.A.. 1 therapy is approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
96%
Small molecule
27 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.
Analysis
Trial Status
28
clinical trials
Clinical Trials
Trial Activity
28 trials
Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT03255694·360 enrolledChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT02375620·96 enrolledChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07450053·128 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)